Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/akt pathway in human pancreatic cancer cells

Pancreas

Volumn 37, Issue 4, 2008, Pages 426-431

  Melstrom, Laleh G ^a   Salabat, Mohammad R ^a   Ding, Xian Zhong ^a   Milam, Benjamin M ^a   Strouch, Matthew ^a   Pelling, Jill C ^a   Bentrem, David J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apigenin; Flavonoid; GLUT 1; Pancreatic cancer; PI3K Akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APIGENIN; CD18 ANTIGEN; GLUCOSE; GLUCOSE TRANSPORTER 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN; AKTIP PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; PROTEIN KINASE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SLC2A1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; EVALUATION; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APIGENIN; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TRANSPORTER TYPE 1; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 58149172000     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181735ccb     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CACancer J Clin. 2007;57(1):43-66.
2. Isselbacher K. Sugar and amino acid transport by cells in culture-differences between normal and malignant cells. N Engl J Med. 1972;286:929-933.
3. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
4. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res. 1996;56:1164-1167.
5. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
6. Younes M, Brown R, Mody DR, et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15(6B):2895-2898.
7. Kalir T, Wang B, Goldfischer M, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer. 2002;94(4):1078-1082.
8. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis and patient survival. Cancer. 2001;92(3): 634-641.
9. Higashi T, Tamaki N, Torizuka T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998;39(10):1727-1735.
10. Yamamoto T, Seino Y, Fukomoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
11. Schek N, Hall BL, Finn OJ. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res. 1988;48:6354-6359.
12. Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004;136:548-556.
13. Fang J, Xia C, Cao Z, et al. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 2005;19:342-353.
14. Duronio V, Scheid MP, Ettinger S. Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal. 1998;10:233-239.
15. Granville CA, Memmott RM, Gills JJ, et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12(3 Pt 1):679-689.
16. Samih N, Hovsepian S, Aouani A, et al. Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. Endrocrinology. 2000;141(1):4146-4155.
17. Ren W, Qiao Z, Wang H, et al. Flavonoids: promising anticancer agents. Med Res Rev. 2003;23(4):519-534.
18. 2/M cell cycle arrest. Mol Cancer. 2006;5:76.
19. Fang J, Xia C, Cao Z, et al. Apigenin inhibits VEGF and HIF-1 expression via PI3K/Akt/p70S6k1 and HDM2/p53 pathways. FASEB J. 2005; 19:342-353.
20. Weldon CB, McKee A, Collins-Burow BM, et al. PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling. Int J Oncol. 2005;26:763-768.
21. Liu LZ, Fang J, Zhou Q, et al. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol. 2005;68:635-643.
22. Ding XZ, Fehsenfeld DM, Murphy LO, et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21(3):310-320.
23. Taniguchi S, Iwamura T, Katsuki T. Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis. 1992;10(4):259-266.
24. Chan CY, Salabat MR, Ding XZ, et al. Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein. Biochem Biophys Res Commun. 2005;328(2):755-764.
25. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
26. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202(3):654-662.
27. Bondar VM, Sweeney-Gotsch, Andreeff M, et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2002;1:989-997.
28. Takeda A, Osaki M, Adachi K, et al. Role of the phosphatidylinositol 3¶-kinaseYAkt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas. 2004;28(3):353-358.
29. Clarke JF, Young PW, Yonezawa K, et al. Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J. 1994;300:631-635.
30. Okada T, Kawano Y, Sakakibara T, et al. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and anti-lipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem. 1994;269:3568-3573.
31. Kohn AD, Summers SA, Birnbaum MJ, et al. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271(49):31372- 31378.